STOCK TITAN
  1. Home
  2. Sec-filings
  3. OFIX
  4. [Form 4] Orthofix Medical Inc. Insider Trading Activity

Orthofix (OFIX) CFO Julie Andrews receives new stock options and RSU grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Orthofix Medical Inc. CFO Julie Andrews received new equity awards consisting of stock options and restricted stock units. On the grant date, she acquired employee stock options for 84,261 shares at an exercise price of $0.00 per share and 35,495 shares of common stock as a restricted stock unit award.

The footnotes state that the restricted stock units and options each vest in three equal annual installments, with one-third of the covered shares vesting on the first, second, and third anniversaries of the grant date. Following these grants, her directly held common stock, including previously reported restricted stock units, totaled 93,534 shares.

Positive

  • None.

Negative

  • None.
Insider Andrews Julie
Role CFO
Type Security Shares Price Value
Grant/Award Employee Stock Option (Right to Buy) 84,261 $0.00 --
Grant/Award Common Stock 35,495 $0.00 --
Holdings After Transaction: Employee Stock Option (Right to Buy) — 84,261 shares (Direct); Common Stock — 93,534 shares (Direct)
Footnotes (1)
  1. Represents a grant of restricted stock units approved by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). The restricted stock units vest with respect to one-third (1/3rd) of the shares of stock covered thereby on the first, second and third anniversary of the Grant Date. Includes 45,590 previously reported restricted stock units. The options vest and become exercisable with respect to one-third (1/3rd) of the shares covered thereby on the first, second and third anniversary of the Grant Date.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Andrews Julie
(Last) (First) (Middle)
3451 PLANO PARKWAY
(Street)
LEWISVILLE TX 75056
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO
3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/03/2026 A 35,495(1) A $0 93,534(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $13.03 03/03/2026 A 84,261 (3) 03/03/2033 Common Stock 84,261 $0 84,261 D
Explanation of Responses:
1. Represents a grant of restricted stock units approved by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). The restricted stock units vest with respect to one-third (1/3rd) of the shares of stock covered thereby on the first, second and third anniversary of the Grant Date.
2. Includes 45,590 previously reported restricted stock units.
3. The options vest and become exercisable with respect to one-third (1/3rd) of the shares covered thereby on the first, second and third anniversary of the Grant Date.
/s/ J. Andres Cedron, attorney-in-fact 03/05/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Orthofix (OFIX) CFO Julie Andrews receive in this Form 4?

Julie Andrews received a grant of employee stock options for 84,261 shares and a restricted stock unit award covering 35,495 shares of Orthofix common stock. Both awards were approved by the Compensation and Talent Development Committee of the company’s Board of Directors.

How do Julie Andrews’ new restricted stock units from Orthofix (OFIX) vest?

The restricted stock units vest in three equal annual installments. One-third of the shares vests on each of the first, second, and third anniversaries of the grant date, aligning the CFO’s equity compensation with longer-term company performance and retention objectives.

What are the vesting terms of Julie Andrews’ Orthofix (OFIX) stock options?

The employee stock options also vest over three years in equal installments. One-third of the option shares becomes exercisable on each of the first, second, and third anniversaries of the grant date, creating a multi-year incentive structure for the CFO’s continued service.

What is Julie Andrews’ Orthofix (OFIX) share count after these equity grants?

After the reported transactions, Julie Andrews directly holds 93,534 shares of Orthofix common stock. This figure includes 45,590 previously reported restricted stock units, as noted in the footnotes accompanying the Form 4 insider transaction disclosure.

Who approved the new equity awards to Orthofix (OFIX) CFO Julie Andrews?

The equity awards were approved by the Compensation and Talent Development Committee of Orthofix’s Board of Directors. This committee administers the plan under which the restricted stock units and stock options were granted, consistent with the company’s executive compensation framework.